Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE-MEXT: Long-term DWP16001 Add-on to Metformin in T2DM
NCT05376969Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Primary endpoint: Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs) at 52 weeks. Started May 2021; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05376969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376969.